Endocannabinoid Modulation: Promising Path for Alcohol Use Disorder
Publication Title: Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies
Summary
- Question
- This study reviewed how modulating the endocannabinoid system (ECS)—a network of receptors and signaling molecules in the brain—could influence alcohol use disorder (AUD). The researchers evaluated evidence from 63 studies, including animal experiments and human trials, to explore whether targeting ECS components could reduce alcohol consumption or improve outcomes for individuals with AUD.
- Why it Matters
- Alcohol use disorder is a chronic condition affecting millions globally, with limited treatment options and varying success rates. The ECS plays a role in regulating reward, stress, and emotional processes, all of which are disrupted in AUD. By understanding how ECS-targeted therapies might work, this research could help develop new treatments for reducing alcohol use, addressing withdrawal symptoms, and preventing relapse, offering hope for patients and clinicians seeking better alternatives.
- Methods
- The researchers conducted a systematic review and meta-analysis of 44 preclinical (animal) studies and 19 human studies. Preclinical studies analyzed how ECS-targeting compounds, such as CB-1 receptor modulators and cannabidiol (CBD), affected alcohol-related behaviors. Human studies varied in design and focused on interventions like rimonabant (a CB-1 receptor blocker) and CBD. Due to differences in methods, human study findings were summarized qualitatively rather than pooled statistically.
- Key Findings
- Preclinical studies showed that CB-1 receptor blockers and CBD consistently reduced alcohol consumption in animals, while CB-1 receptor activators increased it. However, in human trials, rimonabant showed no significant impact on drinking behavior and raised safety concerns, including depression. CBD reduced alcohol cravings and brain activity linked to alcohol cues in some studies, but its effects on actual drinking behavior were inconsistent. Overall, human results lagged behind preclinical promise.
- Implications
- The findings suggest that ECS-targeted therapies, particularly CB-1 receptor blockers and CBD, have potential to reduce alcohol use and related behaviors. However, challenges like safety concerns with rimonabant and inconsistent clinical results highlight the need for safer, more effective ECS-modulating drugs. These therapies could address multiple aspects of AUD, including craving, stress, and relapse risk, offering a more comprehensive treatment approach.
- Next Steps
- The authors emphasize the need for clinical trials exploring newer ECS-targeted compounds, such as neutral CB-1 receptor blockers and enzyme inhibitors, which may offer better safety profiles. Future research should also focus on optimizing dosing, identifying patient subgroups most likely to benefit, and integrating biomarkers to track treatment responses. Long-term studies are crucial to assess efficacy and monitor potential side effects.
- Funding Information
- This research was supported by grants K23DA052682 and R01DA600066 from the National Institute on Drug Abuse (NIDA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Yale University also provided funding and support for this research.
Full Citation
Costa G, Cerezo-Matias M, Funaro M, Bagdas D, Kaye A, Krystal J, Petrakis I, De Aquino J. Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies. Molecular Psychiatry 2026, 31: 3849-3871. PMID: 41760917, PMCID: PMC13269127, DOI: 10.1038/s41380-026-03523-5.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Gabriel P. A. Costa, MD
First AuthorPostdoctoral Associate
Joao P. De Aquino, MD
Last AuthorAssistant Professor of Psychiatry